These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2841996)

  • 1. The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin.
    Carmichael J; Cantwell BM; Edwards CM; Rapeport WG; Harris AL
    BMJ; 1988 Jul; 297(6641):110-1. PubMed ID: 2841996
    [No Abstract]   [Full Text] [Related]  

  • 2. The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice.
    Goddard PM; Jones M; Pollard LA; Valenti MR; Harrap KR
    Cancer Chemother Pharmacol; 1990; 25(5):377-9. PubMed ID: 2155065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy].
    Joss R; Rohrbach D; Buser K; Pirovino M; Karde C; Brunner K
    Schweiz Med Wochenschr; 1989 Jun; 119(23):831-4. PubMed ID: 2549616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Addelman M; Erlichman C; Fine S; Warr D; Murray C
    J Clin Oncol; 1990 Feb; 8(2):337-41. PubMed ID: 2153767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting.
    Falkson G; van Zyl AJ
    Cancer Chemother Pharmacol; 1989; 24(3):193-6. PubMed ID: 2544309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache.
    Couturier EG; Hering R; Foster CA; Steiner TJ; Clifford Rose F
    Headache; 1991 May; 31(5):296-7. PubMed ID: 1650335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRL 43694.
    Cancer Invest; 1989; 7(5):535. PubMed ID: 2559785
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
    Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
    Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.
    Soukop M
    Eur J Cancer; 1990; 26 Suppl 1():S15-9. PubMed ID: 2169779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granisetron (BRL 43694) in the treatment of cytostatic drug-induced emesis: a summary.
    Pintens H
    Cancer Treat Rev; 1990 Sep; 17(2-3):307-10. PubMed ID: 2176932
    [No Abstract]   [Full Text] [Related]  

  • 11. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.
    Bermudez J; Boyle EA; Miner WD; Sanger GJ
    Br J Cancer; 1988 Nov; 58(5):644-50. PubMed ID: 2851311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis.
    Cupissol DR; Serrou B; Caubel M
    Eur J Cancer; 1990; 26 Suppl 1():S23-7. PubMed ID: 2169782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of three dose levels of ICS 205-930 (a selective 5HT-3 antagonist) on cisplatin-induced nausea and vomiting.
    Seinen H; Zonnenberg BA; Tjia P; Neijt JP
    Eur J Cancer Clin Oncol; 1989 Sep; 25(9):1333-5. PubMed ID: 2806357
    [No Abstract]   [Full Text] [Related]  

  • 14. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response.
    Carmichael J; Cantwell BM; Edwards CM; Zussman BD; Thompson S; Rapeport WG; Harris AL
    Cancer Chemother Pharmacol; 1989; 24(1):45-9. PubMed ID: 2541937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of granisetron for nausea and vomiting induced by anticancer drugs--optimal dose-finding study].
    Suminaga M; Furue H; Ohta K; Taguchi T; Niitani H; Ogawa N
    Gan To Kagaku Ryoho; 1993 Jul; 20(9):1203-10. PubMed ID: 8392825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.
    Plosker GL; Goa KL
    Drugs; 1991 Nov; 42(5):805-24. PubMed ID: 1723376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group.
    Smith IE
    Eur J Cancer; 1990; 26 Suppl 1():S19-23. PubMed ID: 2169780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
    Bremer K; Uhlenbusch R
    Dtsch Med Wochenschr; 1991 Nov; 116(48):1817-23. PubMed ID: 1659980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical evaluation of granisetron for nausea and vomiting induced by anticancer drugs--multi-centered placebo-controlled double-blind comparative study].
    Suminaga M; Furue H; Ohta K; Taguchi T; Niitani H; Ogawa N
    Gan To Kagaku Ryoho; 1993 Jul; 20(9):1211-9. PubMed ID: 8392826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRL 43694, a new 5HT3 receptor antagonist, prevents cisplatin-induced emesis in dogs.
    Bhandari P; Gupta YK; Seth SD
    Methods Find Exp Clin Pharmacol; 1989 May; 11(5):361-3. PubMed ID: 2547129
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.